Keywords: strong, ae, profile, vanda, iloperidone, usa-based, pharmaceuticals

Strong AE profile for Vanda's iloperidone

Article | 19 May 2008

Print This

USA-based Vanda Pharmaceuticals has reported strong data on iloperidone, including a four-week, short-term Phase III trial, as well as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in